Latest diabetic neuropathy Stories
RICHMOND, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
SUN VALLEY, Calif., Aug.
XTend Medical has secured the exclusive global distribution rights to DDI's vibration device for pre-screening of diabetic neuropathy.
Immunosyn Corporation (OTCBB:IMYN) announced today that marketing, distribution and patient treatment approval has been granted by the Ministry of Health Malaysia for SF-1019 in the Private Pay Heath Sector in Malaysia. The marketing name for SF-1019 in Malaysia will be R-1818.
The Stanford University Center on Longevity and the U.S.
SAN MATEO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will report results for its second quarter 2008 on Wednesday, August 13, 2008, after the market closes.
RICHMOND, Calif., July 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. today reported second quarter 2008 financial results and accomplishments.
XTL Biopharmaceuticals has completed patient randomization into its Phase IIb study of Bicifadine - a serotonin and norepinephrine reuptake inhibitor - for the treatment of diabetic neuropathic pain. Approximately 350 patients were randomized into the study.
By Napoli, Maryann Many people with diabetes suffer from a painful condition called peripheral neuropathy. The burning, numbness, tingling and throbbing sensations that primarily affect the feet are notoriously resistant to successful treatment.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.